via EurekAlert!
On the road to developing new therapeutic drugs for osteoporosis and other bone degenerative diseases.
Osteoporosis is a disease that causes bones to fracture easily due to a reduction in both bone mass and quality. Aging is one of its leading causes, and it is estimated that around 200 million people are affected worldwide. Fractures of the femoral neck–the connection between the femur and the hip joint–or of vertebrae can leave a person bedridden which increases the need for care, reduces quality of life and systemic function, and increases mortality.
Bone is a living tissue that is repeatedly broken down (bone resorption) and remade (bone formation) little by little every day. If this balance collapses and bone resorption exceeds bone formation, bone density decreases and can lead to osteoporosis. Several medications are available to treat this disease, but the number of drugs that promote bone formation are far fewer compared to those that suppress bone resorption. The development of therapeutic agents that regenerate bones is highly desired.
Sirtuins are enzymes that play important roles in controlling aging, stress responses, various areas of the metabolism, and several other body functions. In mammals, there are seven types of sirtuins, SIRT1 to SIRT7. Although SIRT7 has been reported to be involved in cancer and lipid metabolism, its role in bone tissue and bone aging was unknown.
RESEARCH
1. The effect of SIRT7 on bone formation
Recent experiments performed by a research group led by scientists from Kumamoto University, Japan showed that mice lacking the SIRT7 gene had reduced bone mass. A bone morphometry analysis showed that bone formation and the number of osteoblasts (bone-building cells) had been reduced. Furthermore, the researchers obtained similar results using osteoblast-specific SIRT7 deficient mice, thereby showing that (osteoblast-specific) SIRT7 is important for bone formation.
2. Expression of sirtuins in bone tissue of old mice
Reduced bone formation is common in people with osteoporosis, and the mechanism for this reduction is not well known. To clarify the mechanism, the researchers compared sirtuin (SIRT1, 6, and 7) expression in the skeletal tissue of young and old mice, and found that SIRT7 decreased with age. They then considered that this decrease in SIRT7 in the older specimens may be associated with decreased osteogenesis, and may even be a cause of osteoporosis.
3. The effect of SIRT7 on osteoblast differentiation
When the researchers cultured osteoblasts (in vitro) with decreased SIRT7 expression in their next experiment, the formation of a bone-like mass (calcified nodule) was markedly suppressed compared to cultures of normal osteoblasts. Additionally, the expression of genes indicating osteoblast differentiation was also decreased, thereby revealing that SIRT7 controls the differentiation of osteoblasts.
4. Transcriptional activation of SP7/Osterix by SIRT7
To clarify the mechanism by which osteoblastic SIRT7 positively regulates the differentiation of osteoblasts, researchers investigated the transcription activity of the gene expression regulatory factor essential for osteoblast differentiation. They found that the transcription activity of SP7 (also known as Osterix), a protein known to induce differentiation of pre-osteoblasts into mature osteoblasts and osteocytes, was markedly decreased in osteoblasts that lacked the SIRT7 gene.
They also realized that to get high transcription activation of SP7/Osterix, it is important for SIRT7 to deacylate the 368th lysine residue of the SP7/Osterix protein. In other words, SIRT7 enhances the transcriptional activity of SP7/Osterix by chemically modifying it (deacylating the 368th lysine residue). Furthermore, the researchers were able to recover osteoblast functionality in the calcified nodule formation by introducing a mutant SP7/Osterix, which deacylated the 368th lysine of SP7/Osterix, into the osteoblasts that had reduced SIRT7 expression.
The research group is confident that their results show a new mechanism for SIRT7 as a deacylating enzyme important for transcriptional activation of the gene expression regulator SP7/Osterix and is essential for osteoblast differentiation.
“In situations where SIRT7 does not work sufficiently, such as in an older individual, osteoblast formation is impaired due to low SP7/Osterix transcriptional activity. We believe that this decreased osteogenesis is associated with osteoporosis,” said study leader Dr. Tatsuya Yoshizawa of Kumamoto University. “Our results, show that the regulatory pathway of SIRT7 – SP7 / Osterix is a promising target for new therapeutic agents to treat decreased osteogenesis and osteoporosis.”
Learn more:Â Breaking osteoporosis: New mechanism activates bone-building cellsÂ
The Latest on: Bone degenerative diseases
via Google News
The Latest on: Bone degenerative diseases
- Managing good healthon August 2, 2022 at 3:31 pm
When the Covid-19 pandemic first began, people were worried and panicked, however, the public health crisis was actually not the first global pandemic. In the past, pandemics such as the Black Death ...
- Will concussions kill football? Examining treatment protocols aiming to keep players safeon August 2, 2022 at 7:16 am
Playing through a concussion, we now know, can have long-term consequences, one being chronic traumatic encephalopathy – more widely known as CTE.
- Global Spine Implants Market Trends, Strategies, Opportunities For 2022-2031on August 2, 2022 at 5:57 am
Spine Implants Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026. The Business Research Company's Spine Implants Global Mark ...
- ‘I’m from the government and I’m here to help’on July 30, 2022 at 1:19 pm
There is a drug problem in West Virginia. The courts and the government are trying to solve it. As I understand it, there was a similar problem in Alabama. Personally, I am from Florida so let me ...
- Altamira Therapeutics’ Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journalon July 28, 2022 at 5:47 am
Altamira Therapeutics (“Altamira” or the “Company”) (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of a ...
- Everything you need to know about osteoarthritis in the wriston July 27, 2022 at 5:00 pm
Osteoarthritis (OA) is a degenerative joint disease that can cause pain ... flexible tissue that cushions and protects the ends of bones, allowing them to glide smoothly over each other.
- Do Bright-Colored Fruits and Vegetables Boost Women’s Health?on July 27, 2022 at 6:19 am
Low bone mineral density can be detected in ... endpoint that develops over an entire lifetime. He added: "Most degenerative diseases, like dementia, are as complex as aging itself and involve ...
- Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588on July 27, 2022 at 5:02 am
(Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful completion of its Phase 1 single ...
- Eating more bright-colored fruits, vegetables may boost women's healthon July 25, 2022 at 3:28 pm
Eating more bright-colored fruits and leafy greens that are high in carotenoids may help women live longer and better, a study found.
via Bing News